- Single-center, randomized, double-blind, placebo-controlled pilot trial of 100 critically ill adults with CAM-ICU-confirmed delirium in surgical and trauma ICUs.
- Patients received 2 mg guanfacine or matching placebo nightly for up to 14 days, or until ICU discharge or delirium resolution.
- Median delirium and coma-free days were 2 (IQR 0-6) with guanfacine versus 1 (IQR 0-4) with placebo (p = 0.02) in unadjusted analyses, but not significant after adjustment.
- Feasibility targets were mostly met, with 100% adherence, retention, and data completeness, though COVID-19 limited recruitment to 0.9 patients/week; authors judge the signal worth a multicenter trial.
Neuro
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.
- Pragmatic randomized trial at Mount Sinai Hospital including 7294 surgical patients with preoperative cognitive impairment identified by NLP, MMSE scores, or diagnostic codes.
- Patients were randomized to an AI-driven, non-interruptive EHR decision support tool aimed at anesthesia team adherence, or to routine perioperative care.
- Only 1255 patients (17.2%) had documented delirium assessments; delirium occurred in 35.1% of intervention and 32.7% of control patients (P = .37).
- Best practice adherence did not differ significantly between groups (all P > .05), and the authors call for further work on using these tools effectively.
- Randomized trial of 178 analyzed patients undergoing posterior lumbar interbody fusion, comparing deep and moderate neuromuscular blockade.
- Deep neuromuscular blockade was compared with moderate blockade, with 3-month chronic postsurgical pain incidence as the primary outcome.
- Chronic pain at 3 months was 19.1% with deep block vs 34.8% with moderate block (RR 0.6; 95% CI 0.3-0.9; P = .018), with no significant difference at 6 months (RR 0.8; 95% CI 0.4-1.5; P = .423).
- Deep block was linked to lower CK, myoglobin and LDH on day 1 and better paraspinal muscle preservation on 6-month MRI; authors attribute benefit to less muscle injury.
- This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
- Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
- Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
- Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
- Pragmatic, open-label, multicenter randomized trial of 2508 adults aged 50 or older having elective major noncardiac surgery at 49 UK NHS hospitals.
- Patients were randomized 1:1 to maintenance of general anesthesia with propofol TIVA or volatile inhalational agents, with other perioperative care left to clinician discretion.
- Days alive and at home at 30 days were similar (22.5 vs 22.4 days; incidence rate ratio 1.00, 95% CI 0.99-1.02; adjusted P = .68).
- TIVA was associated with lower reported thirst, hoarseness, and nausea/vomiting; major complications (12.4% overall) did not differ between groups.
- Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
- Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
- Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
- Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.
- Double-blind, placebo-controlled single-center randomized trial of 232 patients aged 60 or older, ASA 1 to 3, undergoing total hip or knee arthroplasty in China.
- Intranasal dexmedetomidine 100 μg versus normal saline given at 21:00 on the night before surgery.
- Delirium within 3 postoperative days occurred in 10.3% versus 20.7% (relative risk 0.50; 95% CI 0.26-0.95; P=0.030) in the intention-to-treat analysis.
- The authors report improved sleep quality and reduced anxiety and pain, with no severe adverse events or nasal mucosal injury, and suggest sleep improvement may partly explain the delirium reduction.
- Prespecified substudy of a single-center randomized trial in 134 randomized adults aged ≥50 undergoing elective CABG and/or valve surgery; 116 completed 3-month follow-up.
- Compared 4-6 weeks of multimodal prehabilitation (exercise, nutritional, and psychological support) with standard preoperative care, with POCD defined by tests 1.5 SD below norms.
- POCD occurred in 28% with prehabilitation vs 22% controls (OR 1.37, 95% CI 0.54-3.50, P = 0.52); preoperative cognitive impairment was strongly associated (OR 13.28).
- Authors conclude prehabilitation did not reduce POCD at 3 months, while higher postoperative physical activity was linked to lower odds (OR 0.97, 95% CI 0.95-1.00, P = 0.047).
- This randomized controlled trial enrolled 100 children aged 4-10 years who were behaviorally noncompliant and undergoing dental procedures under general anesthesia.
- The EEG-guided group titrated sevoflurane to SedLine targets (PSI 25-50, SEF 10-15 Hz), compared with standard management guided by MAC and clinical signs.
- Emergence delirium on arrival to recovery was 17% versus 43%, and maintenance EtSevo was 1.88 vs 1.98 (mean difference 0.10, 95% CI 0.006-0.190, p=0.036).
- The authors urge cautious interpretation given small EEG-derived differences and possible confounding by postoperative pain, and found EEG parameters were not independently associated with delirium within the target ranges.
- Pilot multicenter randomized trial of 35 intubated adults with heatstroke across ten tertiary ICUs in China.
- Compared rapid cooling to 35.0°C held for 48 hours against conventional cooling targeting 36.5–37.5°C, with cooling only above 38.0°C.
- Survival and 28-day poor functional outcome did not differ (17.6% vs 16.7%), but grade 3-4 GI injury (52.9% vs 0%, p<0.001) and arrhythmias (41.2% vs 11.1%, p=0.045) were higher with hypothermia.
- The authors confirmed feasibility for a larger trial and concluded the hypothermia strategy should not be routinely adopted in ICU heatstroke management.
- Randomised non-inferiority trial of 455 patients aged 65 or older undergoing lung resection, with delirium assessed by blinded assessors.
- Remimazolam anaesthesia was compared with propofol anaesthesia for postoperative delirium during the first three postoperative days.
- Delirium occurred in 48% versus 31% of patients (RR 1.53, 95% CI 1.21-1.94), with a 16.5% absolute difference (95% CI 7.7-25.3%) that exceeded the 10% margin.
- Emergence delirium was more frequent with remimazolam (46% vs 28%), and the authors concluded remimazolam was not non-inferior to propofol.
- Double-blind, sham-controlled trial in 80 healthy participants receiving neurofeedback training during capsaicin-induced tonic pain.
- Real feedback rewarded contralateral somatosensory alpha power, while sham feedback was noncontingent; pain ratings and EEG microstates were tracked.
- Real feedback raised targeted alpha power and reduced pain unpleasantness early and sustained, with a later, block-specific drop in intensity; the abstract gives no effect sizes or p-values.
- The authors conclude that alpha neurofeedback mainly modulates affective pain, via dissociable neurocognitive pathways, and suggest it may be a nonpharmacological option.
- Post hoc analysis of 70 of 110 severe TBI patients from the BOOST II randomized trial, across ten U.S. ICUs.
- Background electronic ICP data were compared with bedside-identified minimalist episodes (60 minutes or less, tier 1 treatments only), defined as 5 minutes at 20 mm Hg or higher.
- Electronic data confirmed only 47% of 509 bedside-identified episodes, and 76% of the 286 discordant episodes had average electronic ICP below 20 mm Hg.
- The authors conclude bedside identification may not reliably distinguish sustained ICP episodes and propose open-source, real-time, temporally synchronized electronic definitions.
- Prospective randomized paired-kidney study at one tertiary center, with 40 recipients from 20 brain-dead donor pairs.
- Recipients were randomized to FloTrac-guided goal-directed therapy targeting stroke volume, or to standard CVP-guided therapy.
- GDHT received less intraoperative IV fluid (1,385.0 ± 259.6 vs 1,958.0 ± 877.0 mL, p = 0.011), and rescue vasopressor use was 45% vs 100% (p = 0.001).
- The authors conclude GDHT safely limits fluid and vasopressor needs, while creatinine trajectories and delayed graft function (10%) were identical between groups.